A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.

The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Final Accrual

60

Trial Chairperson

Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC

Clinical Trial Registration

Related Post

24 February, 2026

First patient recruited for trial of new imaging modality for lung cancer

LATEST NEWS: 24 February 2026 The first Australian participant

Roland Towning, participant in TROG NINJA trial
3 February, 2026

Roland’s story

Roland TowningPort Stephens, NSW Roland Towning is taking part